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The use of combination antiretroviral therapy (CART) in HIV-infected patients has resulted in a dramatic decline in AIDS-related
mortality. However, mortality due to non-AIDS conditions, particularly cardiovascular disease (CVD) seems to increase in this
population. CART has been associated with several metabolic risk factors, including insulin resistance, low HDL-cholesterol,
hypertriglyceridemia and postprandial hyperlipidemia. In addition, HIV itself, as well as speciﬁc antiretroviral agents, may
further increase cardiovascular risk by interfering with endothelial function. As the HIV population is aging, CVD may become
an increasingly growing health problem in the future. Therefore, early diagnosis and treatment of cardiovascular risk factors
is warranted in this population. This paper reviews the contribution of both, HIV infection and CART, to insulin resistance,
postprandial hyperlipidemia and cardiovascular risk in HIV-infected patients. Strategies to reduce cardiovascular risk are also
discussed.
1.Introduction
The widespread use of combination antiretroviral therapy
(CART) has led to a dramatic and sustained reduction in the
morbidity and mortality associated with HIV infection and
has transformed this disease into a chronic condition [1, 2].
CART generally consists of two nucleoside analogue reverse-
transcriptaseinhibitors(NRTIs)andaproteaseinhibitor(PI)
or nonnucleoside analogue reverse-transcriptase inhibitor
(NNRTI). Despite an enormous decrease in AIDS-related
mortality, CART has been associated with changes in body
fat distribution and several metabolic risk factors, such
as hypertriglyceridemia, low HDL-cholesterol, and insulin
resistance [3–5]. Moreover, recent studies have shown that
prolonged use of CART is associated with an increased risk
of cardiovascular disease (CVD) [6, 7]. As treatment of HIV
infection has become more successful, CVD may become
an increasingly growing health problem in HIV-infected
patients. This review focuses on the underlying mechanisms
and characteristics of dyslipidemia, insulin resistance, and
CVD in HIV-infected patients.
2. Lipodystrophy
CART in HIV-infected patients is strongly associated with
changes in body fat distribution, often referred to as
lipodystrophy [3–5]. Lipodystrophy is characterized by sub-
cutaneous fat loss, visceral fat accumulation, and develop-
ment of a buﬀalo hump. Subcutaneous fat loss is most
noticeable in the face, limbs, and buttocks and may occur
independently of visceral fat accumulation. The prevalence
of lipodystrophy varies widely, from 10 to 80 percent, and
is mainly dependent on the type and duration of CART
and the criteria used for diagnosing lipodystrophy [3–5].
Severe forms of lipodystrophy, especially lipoatrophy, can be
disﬁguring and stigmatizing and often lead to suboptimal
adherence to CART. All classes of antiretroviral agents may2 International Journal of Vascular Medicine
be related to the development of lipodystrophy, but the
prevalenceandseverityoflipodystrophyareincreasedmostly
in patients treated with the combination of NRTIs and a PI
[3–5]. The etiology of lipodystrophy appears to be multifac-
torial, including HIV drug inhibitory eﬀects on adipocyte
diﬀerentiationandalterationofmitochondrialfunctions.PIs
impede adipocyte diﬀerentiation through altered expression
and nuclear localization of sterol regulatory element-binding
protein-1 (SREBP-1) and peroxisome proliferator-activated
receptor-γ (PPAR-γ), which are essential for adipogenesis
[8]. NRTIs may induce mitochondrial dysfunction and
apoptosis of adipocytes by inhibition of mitochondrial DNA
polymerase-γ and depletion of mitochondrial DNA [9].
3.Dyslipidemia
The natural course of HIV infection is characterized by
reductions in HDL-cholesterol and LDL-cholesterol and an
increase in triglycerides (TGs) [10]. Elevated TGs are due
to a combination of hepatic very low-density lipoprotein
(VLDL) overproduction and reduced TG clearance [10, 11].
Hypertriglyceridemia is related to poor virological control
andincreasedlevelsofTNF-α[10,11].TNF-αinterfereswith
free fatty acid (FFA) metabolism and lipid oxidation and
attenuates insulin-mediated suppression of lipolysis [11].
The nutritional state of HIV-infected patients, including
weight loss and protein depletion, contributes to reduced
HDL-cholesterol and LDL-cholesterol levels [10, 11].
Following the introduction of CART, more pronounced
atherogenic changes in the lipid proﬁle, including increases
in TG and LDL-cholesterol, and a decrease in HDL-
cholesterol, have been observed [3–5]. In addition, increases
inapolipoproteinB(apoB)havebeenfound,oftenassociated
with the predominance of atherogenic small dense LDL
[3–5]. In a large cross-sectional study, the prevalence of
hypercholesterolemia (>6.2mmol/L), hypertriglyceridemia
(>2.3mmol/L), and low HDL-cholesterol (<0.9mmol/L)
was 10 to 27 percent, 23 to 40 percent, and 19 to 27 percent,
respectively, depending on the antiretroviral regimen [12].
The pathogenesis of CART-related dyslipidemia is complex
and involves various drug-induced eﬀects, in association
with hormonal and immunological inﬂuences. Especially PI
therapy has been associated with dyslipidemia. The most
pronounced changes in the lipid proﬁle have been observed
with intensive booster doses of ritonavir [13]. Amprenavir
and nelﬁnavir have intermediate eﬀects on plasma lipids,
while indinavir, saquinavir, and lopinavir have minor eﬀects
on plasma lipids [3–5, 13]. Atazanavir does not negatively
aﬀect the lipid proﬁle [14]. The eﬀects of PIs on the lipid
proﬁle seem to be drug-related, because an interaction with
the host response to HIV or changes in body composition
hasbeenexcludedbyseveralshort-termstudiesconductedin
HIV-negative volunteers [15–17]. In these subjects, ritonavir
increased the concentrations of plasma TG, apoB, and
VLDL-cholesterol as early as 2 weeks after administration
[15]. Administration of lopinavir/ritonavir to healthy HIV-
negative volunteers for 4 weeks resulted in increased TG and
decreased HDL-cholesterol levels [16]. In contrast, Noor et
al. showed that administration of indinavir for 4 weeks to
HIV-negative subjects did not result in signiﬁcant changes in
lipoproteins, TG, or FFA levels but caused insulin resistance
independent of increases in visceral adipose tissue [17].
Apparently, changes in the lipid proﬁle develop as early as
weeks after administration of a PI, independent of HIV
infection or body fat distribution, suggesting direct eﬀects of
PIs on lipid metabolism.
The mechanism of PI-induced dyslipidemia is not fully
understood but is probably multifactorial. First, it has been
suggested that PIs suppress the breakdown of the nuclear
form of SREBP-1 in the liver [18]. SREBP-1 is a master
transcriptional regulator and regulates the expression of
genes involved in FFA, TG, and cholesterol biosynthesis.
Hence, hepatic accumulation of SREBP-1 could result in
increasedhepatic denovolipogenesis. Forexample,ritonavir
hasbeenshowntoincreasethelevelofactiveADD-1/SREBP-
1 protein during adipogenesis [18]. Similarly, indinavir and
nelﬁnavir, butnot amprenavir, altered adipose cell diﬀerenti-
ationandSREBP-1nuclearlocalizationinanadiposecellline
[19]. Second, PIs seem to suppress proteasomal breakdown
of nascent apoB in the liver, leading to increased VLDL
secretion[20].Inhumanhepatoma(HepG2)cells,treatment
with therapeutically relevant concentrations of ritonavir
or saquinavir protected nascent apoB from intracellular
degradation [20]. Whether this is also the case for the
other PIs is not known. A third proposed pathway is based
upon the structural similarity between the catalytic region
of HIV-1 protease and two homologous proteins involved in
lipid metabolism: cytoplasmic retinoic acid-binding protein
type 1 (CRABP-1) and low density lipoprotein-receptor-
related protein (LRP) [4]. CRABP-1 is involved in the
conversion of retinoic acid to cis-9-retinoic acid, which
binds the retinoid X receptor- (RXR-)PPAR-γ heterodimer,
stimulating adipocyte diﬀerentiation and proliferation. PIs
are thought to bind to CRABP-1 and inhibit the formation
ofcis-9-retinoicacid,leadingtoreducedPPAR-γ activityand
peripheral lipoatrophy [4]. Impaired FFA storage capacity in
adipose tissue and increased ﬂux of circulating lipids may
upregulate hepatic VLDL production and, hence, contribute
to hyperlipidemia. LRP normally binds to lipoprotein lipase
(LPL) on capillary endothelium, which hydrolyses FFA from
TG, promoting their accumulation in adipocytes. Remnants
of TG-rich lipoproteins (TRLs) are removed from the cir-
culation by the LDL-receptor and the hypothetical remnant
receptor in the liver. Binding of PIs to LRP would impair
hepatic remnant uptake and TG clearance by the endothelial
LRP-LPL complex [4]. Evidence supporting this concept
has been provided in apoE3-Leiden transgenic mice treated
with ritonavir, demonstrating decreased LPL-mediated TG
c l e a r a n c ea sw e l la si m p a i r e du p t a k eo fT G - d e r i v e dF F Ai n
adipose tissue, which may contribute to lipodystrophy [21].
PI-sparing CART may also aﬀect the lipid proﬁle,
although cholesterol and TG levels generally rise less in
comparison with regimens containing a PI [12, 22]. Of the
NNRTIs, efavirenz is associated with higher levels of choles-
terol and TG than is nevirapine, whereas both increase HDL-
cholesterol [23]. The severity and prevalence of dyslipidemia
in HIV-infected patients may also depend on HIV disease
stage and the concomitant presence of lipodystrophy andInternational Journal of Vascular Medicine 3
insulin resistance [3–5, 12]. The presence of lipodystrophy in
HIV-infected patients has been associated with accelerated
lipolysis, hepatic reesteriﬁcation, and hypertriglyceridemia
[24]. However, although it is likely that increased FFA release
from adipose tissue contributes to the increase in hepatic
VLDL synthesis, other factors must be involved, because
insulin-induced suppression of lipolysis and systemic FFA
availability did not normalize the VLDL-TG secretion rate in
a kinetic study [25].
4.PostprandialLipemia
TRLs are mainly produced in the postprandial phase. A
schematic overview of postprandial TG and FFA metabolism
is shown in Figure 1. Endogenous TRLs (VLDL, contain-
ing apoB100 as structural protein) and exogenous TRLs
(chylomicrons, containing apoB48 as structural protein)
compete for clearance by LPL, which hydrolyzes TG into
glyceroland FFA, leaving atherogenicremnant particles [26].
In the postprandial phase due to limited LPL availability,
competition at the level of LPL will occur resulting in
accumulation of TRL. This competition is most likely when
fasting hypertriglyceridemia is present. The lipolytic rate, as
well as the clearance of remnant particles by liver receptors,
contributes to removal of TRL from the circulation. Adipose
tissue plays a crucial role in regulating FFA concentrations in
the postprandial period by suppressing the release of FFA in
the circulation and stimulating the uptake of FFA liberated
from TRL by LPL [27]. This pathway is also known as the
pathway of adipocyte FFA trapping.
A schematic overview of the proposed mechanism for
hypertriglyceridemia in HIV-infected patients is shown in
Figure 2. First, direct eﬀects of PIs on hepatic TG synthesis
andapoBmetabolism,whichhavebeendescribedindetailin
theprevioussection,mayresultinincreasedVLDLsecretion.
Insulin resistance and the presence of lipodystrophy may
further contribute to hypertriglyceridemia. Adipocyte FFA
trapping is impaired in patients with HIV-lipodystrophy,
because there is not suﬃcient subcutaneous adipose tissue
to provide the necessary buﬀering capacity [28]. If adipocyte
FFA trapping is disturbed, then nonadipose tissues, such
as the liver, skeletal muscle, and pancreas, are exposed to
excessive FFA concentrations. FFA reaching the liver may
contributetoanincreaseinVLDLsynthesis[28].Inaddition,
impaired disposal of intestinal TRL is related to a defect
in LPL activity in HIV-infected patients [28–33]. Especially
the combined use of NRTIs and PIs has been associated
with impaired clearance of TRL [30]. In a kinetic study,
it was shown that HIV-infected patients on CART show
a signiﬁcant reduction in VLDL and IDL apoB fractional
catabolic rates compared with HIV-negative controls, which
was related to peripheral fat loss [31]. Even in fasting
normolipidemicsubjects,CARTresultedinhigherpostpran-
dial remnant lipoprotein levels, irrespective of the CART
regimen [33]. Increasing evidence suggests that postprandial
hyperlipidemia contributes to atherosclerosis [34–37]. Both
hepatic and intestinal TRL and their remnants accumulate
in the subendothelial space, where they promote atheroscle-
rosis by the formation of foam cells [34]. Hence, current
evidence suggests a proatherogenic postprandial lipoprotein
phenotype in CART-treated HIV-infected patients, with
accumulation of remnant lipoproteins.
5. Adipose Tissue
In the general population, postprandial TG and FFA
metabolism is closely related to adipose tissue distribution.
Especially abdominal obesity is associated with insulin
resistance and hypertriglyceridemia [38]. However, abso-
lute or partial lack of body fat may result in a similar
metabolic risk proﬁle. Several forms of congenital and
acquired lipodystrophies have been related to dyslipidemia,
insulin resistance, and early onset DM [39–41]. Similarly, the
presence of CART-associated lipodystrophy in HIV-infected
patients may play a key role in disturbed TG metabolism.
How does the lack of body fat lead to similar manifes-
tations to those seen with an excess of fat? There may be
several explanations. First, experimental evidence indicates
that subcutaneous fat may be considered a “metabolic sink”
that prevents accumulation of harmful ectopic fat [39–41].
Lack of adipose tissue diverts TG and FFA to accumulate
in other organs, such as the liver and skeletal muscle,
leading to hepatic fat accumulation, VLDL overproduction,
and insulin resistance [39–41]. In line with this hypoth-
esis, the presence of HIV-lipoatrophy has been associated
with impaired adipocyte FFA trapping [28], increased fat
content in the liver [42], VLDL overproduction [24, 28],
and impaired disposal of TRL [25, 29]. Most likely, the
eﬀects on dyslipidemia are resulting from lipodystrophy due
to CART, although a role of HIV infection itself cannot
be excluded. Second, in addition to the central role of
lipid storage, adipose tissue also releases a large number
of cytokines and bioactive mediators that inﬂuence body
weight homeostasis, inﬂammation, and insulin sensitivity
[43, 44]. These various protein signals are often referred to
as adipocytokines and include adiponectin, leptin, IL-6, and
TNF-α. Adiponectin levels are inversely related to indices of
insulin resistance [45] and are low in patients with HIV-
lipodystrophy [46, 47]. Low adiponectin levels are associated
with a moderately increased CVD risk in diabetic men [48].
The diﬀerentiation of preadipocytes into mature adipocytes
is a key process contributing to the normal function of
adipose tissue. Subcutaneous adipocytes diﬀer from visceral
adipocytes in many respects. Compared with subcutaneous
adipocytes, visceral adipocytes are hyperlipolytic and have
a distinct secretion proﬁle of adipocytokines [43, 44].
Lipodystrophy is characterized by impaired diﬀerentiation
of preadipocytes to mature adipocytes [8, 9], resulting in
reduced production of leptin and adiponectin [46]. Leptin
deﬁciencyandhypoadiponectinemia correlatewithlipoatro-
phy and visceral fat accumulation in HIV-infected patients,
whereas hypoadiponectinemia also appears to be associated
with insulin resistance and dyslipidemia [47]. Clearly, these
studies emphasize the importance of adipose tissue as an
active endocrine organ involved in several metabolic and
inﬂammatoryprocessesthatarerelevantforthedevelopment
of atherosclerosis. Both, excess of visceral fat and lack of






Figure 1: Postprandial lipid and FFA metabolism. In the postprandial phase, endogenous (VLDL) and exogenous (chylomicrons) TRL
compete for clearance by LPL, which hydrolyzes TG into glycerol and FFA, leaving atherogenic remnant particles. The lipolytic rate, as well
as the clearance of remnant particles by liver receptors, contributes to removal of TRL from the circulation. Adipose tissue plays a crucial
role in regulating FFA concentrations by suppressing the release of FFA in the circulation and stimulating the uptake of FFA liberated from













Figure 2: Pathogenesis of CART-related hyperlipidemia. Several factors contribute to hyperlipidemia in HIV-infected patients. PIs suppress
thebreakdownofthenuclearformofSREBP-1,aswellastheproteasomaldegradationofnascentapoBintheliver,leadingtoincreasedVLDL
secretion (1). In the postprandial phase due to limited LPL availability, competition at the level of LPL will occur resulting in accumulation
of TRL. This competition is most likely when fasting hypertriglyceridemia is present. In addition, impaired disposal of TRL is likely due to
a defect in LPL activity (2) and delayed removal of remnant particles by liver receptors (3). Impaired FFA storage capacity (4) may lead to
increased ﬂux of circulating lipids (5) and upregulate hepatic VLDL production in patients with lipodystrophy.
handling,hypertriglyceridemia,andinsulinresistance,which
is partly mediated by adipocytokines.
6. InsulinResistance
InsulinresistanceiscommonlyseeninHIV-infectedpatients.
Insulin resistance may result from direct eﬀects of antiretro-
viral agents, eﬀects of HIV infection, or indirect eﬀects,
such as changes in body fat distribution [49]. It has
been shown that PIs induce insulin resistance in vitro
by reducing insulin-mediated glucose uptake by glucose
transporter4[50].InHIV-negativeadults,PIsreduceinsulin
sensitivity as early as 4 weeks after administration, without
changing body fat distribution [17, 51, 52]. Direct eﬀects
of NRTIs and NNRTIs on insulin sensitivity have not
been demonstrated, but these classes may contribute to
insulin resistance indirectly through changes in body fat
distribution. Insulin resistance has been related to excess of
visceral fat, loss of subcutaneous fat, and increased waist-to-
hip ratio [3–5]. Basal lipolytic rates are generally increased
in patients with HIV-lipodystrophy, suggesting impaired
action of hormone-sensitive lipase [53]. In addition, several
studies have reported elevated FFA levels following glucose
or insulin challenges, suggesting resistance to the action of
insulin to suppression of lipolysis [54, 55]. The prevalence
of insulin resistance among those treated with CART is up
to 60 percent, depending on the criteria and techniques used
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As a consequence of insulin resistance, abnormalities in
glucose tolerance have been frequently observed in HIV-
infected patients. The prevalence of diabetes mellitus (DM)
was 7 percent in HIV-infected adults with lipodystrophy
compared with 0.5 percent of healthy controls matched for
age and BMI [58]. Impaired glucose tolerance was present in
35 percent of HIV-infected patients compared with 5 percent
of matched controls [58]. The prevalence and incidence
of DM have also been analyzed in the Multicenter AIDS
Cohort Study [59]. In this study, 14 percent of HIV-infected
men had DM compared with 5 percent of HIV-negative
men (prevalence ratio of 4.4 after adjustment for age and
BMI). In addition, DM was 3.1 times as likely to develop
in HIV-infected men receiving CART as it was in control
subjects over a three-year period of observation. Exposure
to a PI-containing regimen, stavudine, or efavirenz was each
independently associated with the development of DM.
7. MetabolicSyndrome
In the general population, several metabolic risk factors
are strongly interrelated and are part of the metabolic
syndrome (MS) as was elegantly described by Reaven in 1988
[60]. The MS encompasses disturbances in glucose, insulin,
and lipid metabolism, associated with abdominal obesity.
The National Cholesterol Education Program (NCEP) has
endorsed the importance of the MS in cardiovascular risk
assessment by introducing a case deﬁnition of the MS
based on clinically easily obtainable anthropometric and
laboratory parameters [61]. Using this deﬁnition, the MS
is present when at least three out of ﬁve risk determinants
(waist circumference ≥88cm in women and ≥102cm in
men, TG ≥1.7mmol/L, HDL-cholesterol ≤1.20mmol/L in
women or ≤1.0mmol/L in men, glucose ≥6.1mmol/L or
blood pressure ≥130/85mmHg) are present [61]. The MS
aﬀects 24 percent of the adult population in the U.S. [62]
and 15 percent of nondiabetic adult Europeans [63] and is
associated with an increased risk of CVD [64] .T h eM Si s
closely linked abdominal obesity [38], but absolute or partial
lack of body fat may result in a similar metabolic risk proﬁle
[39–41].
Several studies focused on the prevalence and charac-
teristics of the MS in HIV-infected patients and possible
related factors. The prevalence of the MS ranges from 17
to 42 percent and is partly dependent on the deﬁnition
used [65–71]. In a study of Jeric´ o et al., the prevalence of
the MS was 17 percent among HIV-infected patients and
was independently associated with age, BMI, and past and
present PI exposure [65]. In a report by Samaras et al., the
prevalence of MS was 18 percent by NCEP criteria [66].
In this study, half of the patients had at least two features
of MS but were not classiﬁed as having MS as their waist
circumference was in the non-MS range. MS was more
common in those currently receiving PIs and was associated
with a substantially increased prevalence of DM in this
speciﬁc cohort. In a study of Jacobsen et al.,a l m o s to n e
quarter of the HIV-infected adults had the MS [67]. Most
patients with the MS had low HDL-cholesterol and high TG
plus ≥1 additional abnormality. The incidence of MS was
higher with increasing viral load, higher BMI and higher
trunk-to-limb fat ratio, and lopinavir/ritonavir or didano-
sine use. Mondy et al. reported that the overall prevalence
of the MS was similar between HIV-infected patients (26
percent) and HIV-negative persons (27 percent), although
the HIV-infected patients had a signiﬁcantly smaller waist
circumference, lower BMI, lower HDL-cholesterol, higher
TG, and lower glucose levels, compared with the subjects
from the NHANES cohort [68]. High prevalence of the MS
was reported by three separate studies, ranging from 35 to 42
percent [69–71]. In the Data Collection on Adverse Events of
Anti-HIV Drugs (DAD) study, for all deﬁnitions considered,
there was an increasing prevalence of the MS over time,
although the prevalence estimates themselves varied widely
[71]. Using an NCEP deﬁnition that was modiﬁed to take
account of the use of lipid-lowering and antihypertensive
medication and measurement variability, an increase in
prevalence from 19 percent in 2000/2001 to 42 percent in
2006/2007 was found.
The risk of developing the MS seems to be related to
HIV-infection, speciﬁc antiretroviral agents and body fat
distribution [65–71]. The MS in HIV-infected patients is
diagnosed mostly through low HDL-cholesterol and high
TG. Frequently, HIV-infected patients do not meet waist
circumference criteria for the MS, despite high rates of
body fat partitioning disturbances. The high lipodystrophy
prevalence rates and skewing of BMI towards normal may
partly explain the relatively low prevalence of the MS in
HIV-infected patients compared with that of the general
population, in which higher obesity rates are found. Thus,
NCEP criteria may underestimate the prevalence of the MS
in HIV-infected patients. It should also be noted that the
presence of the MS in HIV-infected individuals does not
appear to increase CVD risk over and above that conferred
by the components of the MS separately [72]. Hence, it is
unclear whether the MS has additive value in cardiovascular
risk assessment of HIV-infected patients.
8. SurrogateMarkersof Atherosclerosis
Endothelial dysfunction is an early marker of atherosclerosis
and can be assessed clinically by ultrasound assessment of
brachial artery ﬂow-mediated vasodilation (FMD). FMD
is correlated with the severity and extent of coronary
sclerosis [73] and predicts future cardiovascular events [74].
Ultrasound measurement of carotid intima-media thickness
(IMT) is a well-accepted, noninvasive method of assessing
early changes in vascular structure and is widely used as a
surrogatemarkerforatheroscleroticdisease[75].Assessment
of both preclinical atherosclerotic markers may provide
important information on the functional and structural
stages of atherosclerosis.
In a cross-sectional study of HIV-infected adults, it
was shown that those on a PI-containing regimen had
markedly impaired FMD compared with those not taking
PIs [76]. However, FMD was not compared with an HIV-
negative reference group, and the relative contributions
of CART, HIV infection, and metabolic risk factors were
diﬃcult to identify. Francisci et al. performed a retrospective6 International Journal of Vascular Medicine
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Figure 3: Pathogenesis of CVD in HIV-infected patients. HIV infection itself has been associated with subclinical atherosclerosis due to a
low-grade inﬂammatory response leading to endothelial dysfunction. CART may promote atherosclerosis through its eﬀects on body fat
distribution, lipid metabolism and insulin sensitivity. Presumably, both HIV infection and CART promote atherosclerosis, either directly or
indirectly via metabolic risk factors.
cohort study in HIV-infected patients before and after
starting CART and matched healthy controls [77]. Soluble
markers of endothelial function were signiﬁcantly higher
in HIV-infected patients before starting CART than in
healthy controls. Short-term treatment with CART reduced
some markers of endothelial dysfunction, with no diﬀer-
ences between PIs and NNRTIs. In a prospective cross-
sectional study by Ross et al., endothelial markers were
also higher in CART-naive patients compared with healthy
controls but were similar between HIV-patients on CART
and healthy controls [78]. Strong correlations were found
between inﬂammatory cytokines and endothelial markers.
Hence,bothstudieshighlightapotentialassociationbetween
inﬂammation and endothelial activation [77, 78]. The
endothelium could be activated either directly by HIV or
by a leukocyte-mediated inﬂammatory cascade triggered by
HIV infection [79–81]. In recent years, a prominent role
for inﬂammation in the pathogenesis of atherosclerosis has
emerged and circulating inﬂammatory molecules have been
identiﬁed as markers of atherosclerotic risk [82]. Antiretro-
viralagentsmayalsodirectlyinduceendothelialdysfunction.
For example, when healthy volunteers were given the PI
indinavirfor4weeks,signiﬁcantendothelialdysfunctionwas
observed, independent of the lipid proﬁle [83, 84]. Unlike
the dramatic impairment seen with indinavir, the newer PIs
atazanavirandlopinavir/ritonavirdidnotinduceendothelial
dysfunction in healthy subjects [85]. Finally, endothelial
dysfunction has also been related to metabolic risk factors.
In one study, the presence of the MS in HIV-infected patients
was associated with markedly impaired FMD [69]. FMD was
related to several metabolic parameters, such as dyslipidemia
and insulin resistance [69].
Structural vascular abnormalities are also present in
HIV-infected patients. Carotid IMT is higher in HIV-
infected patients than in age-matched controls [86, 87],
and progresses much more rapidly than previously reported
rates in non-HIV cohorts [88]. In HIV-infected patients,
IMT is related to several traditional risk factors [69, 86–
88] but when a control group was added to the analysis,
HIV infection was also an independent predictor of IMT
[88]. Furthermore, progression of IMT has been related to
low nadir CD4 cell counts [88]. Even after adjustment for
traditional risk factors, HIV-infected patients have greater
carotid IMT than controls [89]. In one study, the association
betweenHIVinfectionandcarotidIMTwassimilartothatof
traditional risk factors, such as smoking [89]. Inﬂammatory
and endothelial activation markers have been associated
with increased carotid IMT, supporting a potential role
of inﬂammation in CVD in HIV-infected patients [90].
Increased carotid IMT has also been related to CART. In
a cross-sectional study of Jeric´ oe ta l ., 42 percent of the
HIV-infectedpatientshadsubclinicalcarotidatherosclerosis,
deﬁned by carotid IMT >0.8mm or the presence of plaque
[91]. Exposure to CART was independently associated with
subclinical carotid atherosclerosis in this study. Finally, HIV-
infected individuals with the MS may be at increased risk
for atherosclerosis based on higher carotid IMT [69, 92].
HIV-infected patients with the MS were more likely to have
ac a r o t i dI M T>0.8mm than were those without MS. Any
positive coronary artery calcium score was more likely to
occur for participants with MS [92].
Taken together, most studies support the concept that
HIV-infected patients are at risk for accelerated atherosclero-
sis. As illustrated in this section, the underlying mechanism
is probably multifactorial, which is schematically depicted
in Figure 3. The HIV infection itself may directly induce
insulin resistance and dyslipidemia, including hypertriglyc-
eridemia and low HDL-cholesterol. Furthermore, chronic
HIV infection is associated with a proinﬂammatory state
leading to endothelial dysfunction. CART may also promote
atherosclerosis through mechanisms involving endothelial
cells, either directly or indirectly via metabolic risk factors.
9.CardiovascularDisease
Use of CART in HIV-infected patients has been associated
with a large beneﬁt in terms of mortality [1, 2]. In a
large retrospective study, this beneﬁt was not diminished
by any increase in the rate of CVD [1]. However, this
study was conducted among 36,766 patients who received
care for HIV infection between 1993 and 2001, and longer-
term observations and analyses are required. Since then,
several studies on CVD endpoints have been published, of
whichmostdemonstrateincreasedCVDriskinHIV-infected
patients. In the DAD study, CART was independentlyInternational Journal of Vascular Medicine 7
associated with a 26 percent relative increase in the rate
of myocardial infarction (MI) per year of exposure during
the ﬁrst four to six years of use [6]. However, the absolute
risk of MI was relatively low. Hypercholesterolemia, older
age, smoking, DM, male sex, and a prior history of CVD
were also associated with an increased risk of MI [6]. A
central question is whether this observed risk is attributable
to all classes of antiretroviral drugs or only to speciﬁc drugs.
Subsequent analyses of the DAD study have demonstrated
that particularly those exposed to PIs and those recently
exposed to the NRTIs abacavir and didanosine had increased
risk of MI [93, 94]. In contrast, no association was found
between the risk of MI and exposure to NNRTIs or any of
the other NRTIs [93–96]. The eﬀect of PIs may be in part a
consequence of the eﬀects of these agents on lipid levels [93].
In contrast, associations between MI risk and abacavir and
didanosine exposure were largely conﬁned to those patients
with recent exposure to the drugs and did not appear to be
driven by dyslipidemia [94, 96]. Abacavir may cause vascular
inﬂammation [96].
Triant et al. conducted a health care system-based cohort
study using a large data registry with 3,851 HIV and
1,044,589 non-HIV patients [7]. MI rates were determined
amongpatientsreceivinglongitudinalcarebetween1996and
2004. MI rates and cardiovascular risk factors were increased
in HIV compared with non-HIV patients. The relative risk of
acute MI was 1.75 in HIV-infected patients after adjustment
for age, sex, race, hypertension, diabetes, and dyslipidemia.
The increased MI event rate was seen over multiple age
ranges and, thus, likely to be clinically signiﬁcant. It should
be noted that the rate of MI was higher among HIV
patients in this study than in the DAD study, but this study
included older patients and was from a U.S. population, with
potentially diﬀerent MI rates and cardiovascular risk factors
than the European-based population of the DAD study.
Inﬂammation appears to be an important pathogenic
event in the progression of atherosclerosis [82]. Premature
atherosclerosis has been reported in young adults with HIV
infection in the pre-CART era [97]. Also, interruption of
CART seems to be associated with an increased short-term
risk of CVD [98]. Infection-induced chronic inﬂammation
may thus contribute to the increased incidence of CVD in
HIV-infected patients. In line, low CD4 cellcounts have been
associated with incident CVD in the HIV Outpatient Study
[99]. CD4 cell count ≤500 cells/mm3 was an independent
risk factor for incident CVD, comparable in attributable risk
to several traditional CVD risk factors [99]. Thus, traditional
risk factors, HIV infection, and antiretroviral agents have
all been associated with CVD endpoints in HIV-infected
patients.
1 0 .T r eatm e n to fR is kF ac t o rs
Dyslipidemia and insulin resistance are important mod-
iﬁable risk factors in HIV-infected patients. Preliminary
data indicate increased cardiovascular morbidity among
HIV-infected patients, suggesting that measures to reduce
cardiovascular risk should be provided. It has been recom-
mended that HIV-infected adults undergo evaluation and
treatment on the basis of NCEP guidelines for dyslipidemia,
with particular attention to potential drug interactions with
antiretroviral agents and maintenance of virological control
of HIV infection [61, 100]. In general, treatment guidelines
outlined by the American Diabetes Association (ADA) and
European Association for the Study of Diabetes (EASD)
should be followed in HIV-infected patients with DM.
10.1. Lifestyle Modiﬁcation. Cigarette smoking is the most
important modiﬁable risk factor among HIV-infected
patients. In the DAD study, more than 50 percent of the
patients were current or former smokers, and smoking
conferred a more than 2-fold risk of MI [6, 12]. Cessation of
smoking is likely to reduce CVD in this population. Manage-
ment of dyslipidemia must include nondrug interventions,
such as a prudent diet, reduced total caloric intake, attaining
ideal bodyweight, and increased physical activity. Routine
aerobic activity and muscle conditioning improved trunk
adiposity and lipid parameters in HIV-infected patients
[101–103]. A recent randomized study showed that dietary
intervention in CART-naive HIV-infected patients prevented
development of dyslipidemia after 6 and 12 months [104].
Structured exercise plus diet decreased total cholesterol and
TG by 11% and 21%, respectively, in HIV-infected patients
[105]. HIV-infected patients with hypertriglyceridemia may
also beneﬁt from omega fatty acids [106, 107].
10.2. Switching Cart. Another strategy to improve dyslipi-
demia is switching antiretroviral agents. Switching antiretro-
viral agents has the potential advantage of avoiding pharma-
cologic intervention for elevations in lipid levels. Switching
from the PI nelﬁnavir to the PI atazanavir reduced total
cholesterol and TG with no apparent antiviral compromise
[108]. Other studies have shown that switching a PI for
either an NNRTI or NRTI, such as nevirapine, efavirenz,
or abacavir, in patients with long-lasting viral suppression
hasantiviraleﬃcacysimilartoearlierPI-basedcombinations
and may partly reverse atherogenic lipoprotein changes
[109–113].
10.3. Lipid-Lowering Agents. Because of the potential for
signiﬁcant drug interactions with commonly used antiretro-
viral drugs, the choices of lipid-lowering agents should be
limited to those agents with a low likelihood of interactions.
HMG-CoA reductase inhibitors or statins are used as ﬁrst-
line therapy for hypercholesterolemia and reduce the risk
of CVD in the general population. Several statins have
been studied in HIV-infected patients. For patients receiving
CART or other medications that inhibit CYP3A4, lovastatin
and simvastatin should be avoided, and atorvastatin and
rosuvastatin should be used with caution. In CART-treated
HIV-infected patients, treatment with pravastatin was asso-
ciated with improvement of the lipid proﬁle and endothelial
function [114, 115]. Others have suggested that atorvastatin
and rosuvastatin are preferable to pravastatin for treatment
of HIV-associated dyslipidemia, due to greater reductions
in LDL-cholesterol and non-HDL-cholesterol, with similar
low toxicity rates [116]. In this report, the likelihood of
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with the use of rosuvastatin (OR 2.1) and atorvastatin (OR
2.1) compared with that of pravastatin. A recent analysis of
829 patients has shown that dyslipidemia is more diﬃcult to
treatinHIV-infectedpatientsthaninthegeneralpopulation,
as illustrated by smaller reductions in LDL-cholesterol and
TG with lipid-lowering agents [117].
Fibrates, synthetic agonists for PPAR-α,h a v eaw e l l -
established tolerability and eﬃcacy proﬁle for patients with
hypertriglyceridemia and mixed hyperlipidemia. Gemﬁ-
brozil, fenoﬁbrate, and bezaﬁbrate have been associated with
improvements of the lipid proﬁle in HIV-infected patients
[118–120]. There are no signiﬁcant drug-drug interactions
among PIs and ﬁbrates. So far, the results of clinical trials
on CVD endpoints with ﬁbrates have been disappointing.
However, the absolute beneﬁts of fenoﬁbrate are likely
to be greater when MS features, including hypertriglyc-
eridemia, are present [121]. Thus, ﬁbrates would seem to
be the preferred treatment for HIV-infected patients with
dyslipidemia characterized mainly by hypertriglyceridemia.
At the present time, there is no compelling reason to
prefer fenoﬁbrate to gemﬁbrozil in HIV-infected patients.
Modest LDL-cholesterol lowering with ezetimibe has also
been observed in HIV-infected patients, although its eﬀect
on CVD endpoints is unclear [122, 123].
10.4. Insulin-Sensitizing Agents. Because of the severity of
insulin resistance in many HIV-infected patients with DM,
it is reasonable to favor insulin sensitizers over insulin
secretagogues.Insulin-sensitizingagentshavealsobeenstud-
ied in nondiabetic HIV-infected patients. In patients with
lipoatrophy, metformin should be used with caution because
further reductions in subcutaneous fat may be seen. On
the other hand, studies with metformin have demonstrated
signiﬁcant reduction of visceral fat and improvement of
insulin sensitivity, lipid levels, and endothelial function
[124–127]. Thiazolidinediones, synthetic agonists for PPAR-
γ, can be considered the preferred approach in those with
lipoatrophy, given the possibility of increasing subcutaneous
fat, albeit modest [127–130]. Of the thiazolidinediones,
rosiglitazone improves insulin sensitivity, but most studies
found detrimental eﬀects on lipid levels [127–130]. In one
study, rosiglitazone improved postprandial adipocyte FFA
trapping but caused a marked increase in postprandial
remnant lipoprotein levels, which may adversely aﬀect
cardiovascular risk [131]. The other registered thiazolidine-
dione, pioglitazone, also improves insulin sensitivity and is
associated small beneﬁts on fasting lipid proﬁle in HIV-
infected patients [132, 133]. However, pioglitazone is partly
metabolized by CYP3A4, increasing the risk of clinically
relevant drug interactions with PIs.
11. Conclusions
In HIV-infected patients, the use of CART is associated
with changes in body composition, dyslipidemia, and insulin
resistance. Disturbed adipose tissue distribution and altered
secretion of adipocytokines may play a key role in the
development of hypertriglyceridemia and insulin resistance.
Presumably, both HIV infection and CART may contribute
to increased CVD risk in HIV-infected patients. The absolute
CVD risk, however, is still relatively small and side eﬀects of
CART should be balanced against the large beneﬁt in terms
of AIDS-related mortality. Nonetheless, as HIV-infected
patients live longer on CART, CVD could become increas-
ingly prevalent in the future. Guidelines for the evaluation
and treatment of dyslipidemia have been provided. Current
treatment options include lifestyle modiﬁcation, switching
antiretroviral agents, and use of lipid-lowering and insulin-
sensitizing agents. Future research will give more insight into
the pathophysiology of CVD in HIV-infected patients and
the role of CART and adipose tissue.
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